A Decision-Analysis Tool for Benefit-Risk Assessment of Nonprescription Drugs
Author:
Affiliation:
1. Department of Medicine; Harbor-UCLA Medical Center; Torrance, CA; USA
2. Kings College; London; United Kingdom
3. University of Stuttgart; Stuttgart; Germany
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference34 articles.
1. A quantitative approach to benefit-risk assessment of medicines-part 1: the development of a new model using multi-criteria decision analysis;Mussen;Pharmacoepidemiol Drug Saf.,2007
2. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework;Lynd;Pharmacoepidemiol Drug Saf.,2010
3. Application of the BRAT framework to case studies: observations and insights;Levitan;Clin Pharmacol Ther.,2011
4. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines;Coplan;Clin Pharmacol Ther.,2011
5. Changing the status of drugs from prescription to over-the-counter availability;Brass;N Engl J Med.,2001
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A proposal for using benefit-risk methods to improve the prominence of adverse event results when reporting trials;Trials;2024-06-22
2. Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM;Clinical Therapeutics;2024-03
3. Questions in self‐selection studies used in consumer research for nonprescription drug candidates: Limitations and recommendations;Clinical and Translational Science;2024-01-31
4. Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts;Frontiers in Pharmacology;2023-10-09
5. Why are self-medication opportunities limited in Austria? An interview study and comparison with other countries;PLOS ONE;2021-01-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3